Hypercoagulation detected by Rotational Thromboelastometry predicts mortality in COVID-19: A risk model based on a prospective observational study

Lou M. Almskog; Agneta Wikman; Jonas Svensson; Matteo Bottai; Mariann Kotormán; Carl-Magnus Wahlgren; Michael Wanecek; Jan van der Linden; Anna Ågren

doi:10.1101/2021.04.29.21256241

ABSTRACT

Background Severe disease due to COVID-19 has been shown to be associated with hypercoagulation. Early identification of prothrombotic patients may help guiding anticoagulant treatment and improve survival. The aim of this study was to assess Rotational Thromboelastmetry (ROTEM^®) as a marker of coagulopathy in hospitalized COVID-19 patients.

Methods This was a prospective, observational study. Patients hospitalized due to a COVID-19 infection were eligible for inclusion. Conventional coagulation tests and ROTEM were taken after hospital admission, and patients were followed for 30 days. Patient characteristics and outcome variables were collected, and a prediction model including variables age, respiratory frequency and ROTEM EXTEM-MCF, was developed using logistic regression to evaluate the probability of death.

Results Out of the 141 patients included, 18 (13%) died within 30 days. D-dimer (p=0.01) and Activated Partial Thromboplastin Time (APTT) (p=0.002) were increased, and ROTEM EXTEM-/INTEM-CT (p<0.001) were prolonged in non-survivors. In the final prediction model, the risk of death within 30 days for a patient hospitalized due to COVID-19 was increased with increased age, respiratory frequency and EXTEM-MCF. Longitudinal ROTEM data in the severely ill subpopulation showed enhanced hypercoagulation. In our in vitro analysis, no heparin effect on EXTEM-CT was observed, supporting a SARS-CoV-2 effect on initiation of coagulation.

Conclusions Here we show that hypercoagulation measured with ROTEM predicts 30-day mortality in COVID-19. Longitudinal ROTEM data strengthen the hypothesis of hypercoagulation as a driver of severe disease in COVID-19. Thus, ROTEM may be a useful tool to assess disease severity in COVID-19, and could potentially guide anticoagulation therapy.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by a grant from the Swedish Society of Thrombosis and Haemostasis (LA), an unrestricted grant from CSL Behring (AW) and grants from Karolinska Institutet (JvdL).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

the Swedish Ethical Review Authority, D-nr 2020-01875

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Shared upon request.

List of abbreviations

(ROTEM): Rotational Thromboelastmetry
(EXTEM): Extrinsically activated assays with tissue factor
(MCF): Maximum Clot Firmness
(APTT): Activated Partial Thromboplastin Time
(CT): Coagulation Time
(INTEM): Intrinsically activated assays using phospholipid and ellagic acid
(COVID-19): Corona virus disease 2019
(SARS-CoV-2): Severe acute respiratory syndrome coronavirus 2
(ICU): Intensive Care Unit
(CCT): Conventional coagulation test
(PCR): Polymerase chain reaction
(CT): Computed tomography
(NIV): Non-invasive ventilation
(NHF): Nasal high flow oxygen therapy
(COPD): Chronic obstructive pulmonary disease
(INR): International Normalized Ratio
(LMWH): Low Molecular Weight Heparin
(FIBTEM): Fibrin-based extrinsically activated assays with tissue factor and platelet inhibitor cytochalasin D
(HEPTEM): Intrinsically activated assays with the addition of heparinase
(CFT): Clot Formation Time
(LI): Lysis Index
(BMI): Body mass index
(AUC): Area under the curve
(ROC): Receiver operating characteristic
(IQR): Interquartile range
(STROBE): Strengthening the Reporting of Observational Studies in Epidemiology
(DOAC): Direct oral anticoagulants
(RF): Respiratory frequency
(PAI-1): Plasminogen activator inhibitor type 1

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.